ATE512232T1 - Expressionssystem mit einem säuger-beta-actin- promotor - Google Patents

Expressionssystem mit einem säuger-beta-actin- promotor

Info

Publication number
ATE512232T1
ATE512232T1 AT04819918T AT04819918T ATE512232T1 AT E512232 T1 ATE512232 T1 AT E512232T1 AT 04819918 T AT04819918 T AT 04819918T AT 04819918 T AT04819918 T AT 04819918T AT E512232 T1 ATE512232 T1 AT E512232T1
Authority
AT
Austria
Prior art keywords
promoter
promoters
actin promoter
expression system
mammalian
Prior art date
Application number
AT04819918T
Other languages
English (en)
Inventor
Hiroyuki Tsunoda
Kiyoshi Habu
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE512232T1 publication Critical patent/ATE512232T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
AT04819918T 2003-12-03 2004-12-03 Expressionssystem mit einem säuger-beta-actin- promotor ATE512232T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003405269 2003-12-03
PCT/JP2004/018006 WO2005054467A1 (ja) 2003-12-03 2004-12-03 哺乳類βアクチンプロモーターを利用した発現系

Publications (1)

Publication Number Publication Date
ATE512232T1 true ATE512232T1 (de) 2011-06-15

Family

ID=34650208

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04819918T ATE512232T1 (de) 2003-12-03 2004-12-03 Expressionssystem mit einem säuger-beta-actin- promotor

Country Status (9)

Country Link
US (1) US8298816B2 (de)
EP (2) EP1707629B1 (de)
JP (2) JPWO2005054467A1 (de)
KR (1) KR20060123413A (de)
CN (1) CN1914320A (de)
AT (1) ATE512232T1 (de)
AU (1) AU2004295590B2 (de)
CA (1) CA2548185A1 (de)
WO (1) WO2005054467A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9738905B2 (en) * 2006-12-20 2017-08-22 Ji Chang You Vector for expressing NC protein of HIV and method for producing NC protein using the same
KR101840994B1 (ko) 2007-12-05 2018-03-21 추가이 세이야쿠 가부시키가이샤 항ｎｒ１０ 항체 및 그의 이용
JP2010104326A (ja) * 2008-10-31 2010-05-13 Japan Health Science Foundation 加齢黄斑変性モデル動物、及び、その作成方法
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
KR101038126B1 (ko) 2010-11-30 2011-05-31 주식회사 엘지생명과학 새로운 융합 프로모터 및 이를 포함하는 재조합 벡터
FR2981946B1 (fr) * 2011-10-28 2015-02-20 Lfb Biotechnologies Unites de transcription et leur utilisation dans des vecteurs d'expression (yb2/0)
FR2986536A1 (fr) * 2012-02-08 2013-08-09 Lfb Biotechnologies Unites de transcription et leur utilisation dans des vecteurs d'expression (cho)
EP2684959A1 (de) * 2012-07-10 2014-01-15 Laboratorios Hipra, S.A. Vektoren zur Transformation von Mycoplasma hyopneumoniae, transformierte Stämme von Mycoplasma hyopneumoniae, sowie deren Verwendung
CN103525868B (zh) * 2013-10-17 2015-01-21 百泰生物药业有限公司 哺乳动物细胞高效表达载体的构建及应用
CN103525867B (zh) * 2013-10-17 2015-01-21 北京东方百泰生物科技有限公司 用于高表达细胞株开发的载体的构建及应用
CN105037560B (zh) * 2015-08-06 2019-02-05 中国农业科学院生物技术研究所 培育表达shTRAIL植物的方法
CN113166782A (zh) * 2018-09-20 2021-07-23 国立大学法人东京医科齿科大学 增强慢病毒载体产生的方法
CN110484563B (zh) * 2019-07-25 2023-04-07 新乡医学院 哺乳动物细胞组合表达载体、表达系统、制备方法和应用
US20230302158A1 (en) * 2020-08-14 2023-09-28 Allen Institute Artificial expression constructs for modulating gene expression in striatal neurons
EP4217376A4 (de) * 2020-09-24 2024-10-09 University of Massachusetts Für nf1 codierende aav-vektoren und verwendungen davon
CN112481418A (zh) * 2020-12-25 2021-03-12 湖南丰晖生物科技有限公司 一种实时荧光定量pcr引物及其应用
EP4036238A1 (de) * 2021-01-27 2022-08-03 The University Court of the University of Edinburgh Funktionelles nukleinsäuremolekül und verfahren
KR102737145B1 (ko) 2023-07-10 2024-12-09 대한민국 신규 발현 벡터 및 이의 용도
KR102737146B1 (ko) 2023-07-10 2024-12-09 대한민국 신규 발현 벡터 및 이의 용도

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
AU629554B2 (en) * 1988-06-24 1992-10-08 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Exogenous gene expression vector containing chick beta-actin gene promoter
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
AU668349B2 (en) * 1991-04-25 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
JPH07502510A (ja) 1991-12-17 1995-03-16 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 嚢胞性繊維症膜貫通型コンダクタンス調節活性（ｃｆｔｒ）のための遺伝子治療
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
EP0652950B1 (de) 1992-07-24 2007-12-19 Amgen Fremont Inc. Bildung von xenogenen antikörpern
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
EP0754225A4 (de) 1993-04-26 2001-01-31 Genpharm Int Heterologe antikörper produzierende transgene nicht-humane tiere
GB9415319D0 (en) 1994-07-29 1994-09-21 Medical Res Council HSV viral vector
DE19516776A1 (de) 1995-05-10 1996-11-14 Boehringer Ingelheim Int Chromatin-Regulatorgene
US7622300B2 (en) * 1998-06-03 2009-11-24 Kappes John C Trans-lentiviral vector particles and transduction of eukaryotic cells therewith
GB9819912D0 (en) 1998-09-11 1998-11-04 Univ Edinburgh Propagation and/or derivation of embryonic stem cells
AU2001290984A1 (en) 2000-09-18 2002-04-02 Genzyme Corporation Expression vectors containing hybrid ubiquitin promoters
DE10128832A1 (de) 2001-06-15 2003-02-06 Jochen Reis Vektor und dessen Verwendung in gentherapeutischen Verfahren
NZ535100A (en) 2002-03-20 2008-04-30 Univ Florida RAAV vector compositions and methods for the treatment of choroidal neovascularization
WO2003093479A1 (en) 2002-05-01 2003-11-13 University Of Florida Research Foundation, Inc. Improved raav expression systems and methods for enhancing transduction of mammalian neural cells
CA2483915A1 (en) 2002-05-02 2003-11-13 University Of Rochester Vectors having both isoforms of b-hexosaminidase
US20030224477A1 (en) * 2002-05-31 2003-12-04 Heartlein Michael W. Optimized promoter constructs
US20060099709A1 (en) 2002-10-01 2006-05-11 Chuan-Yuan Li Targeted tumor therapy by use of recombinant adenovirus vectors that selectively replicate in hypoxic regions of tumors
CN103173447B (zh) * 2003-06-24 2016-12-21 建新公司 新的β-肌动蛋白和RPS21 启动子及其应用

Also Published As

Publication number Publication date
JPWO2005054467A1 (ja) 2007-12-06
EP2270152A1 (de) 2011-01-05
EP1707629A1 (de) 2006-10-04
US20080250514A1 (en) 2008-10-09
KR20060123413A (ko) 2006-12-01
JP2012070744A (ja) 2012-04-12
AU2004295590B2 (en) 2010-04-29
CA2548185A1 (en) 2005-06-16
CN1914320A (zh) 2007-02-14
US8298816B2 (en) 2012-10-30
WO2005054467A1 (ja) 2005-06-16
EP1707629B1 (de) 2011-06-08
AU2004295590A1 (en) 2005-06-16
EP1707629A4 (de) 2007-12-12

Similar Documents

Publication Publication Date Title
ATE512232T1 (de) Expressionssystem mit einem säuger-beta-actin- promotor
Rowe et al. De novo DNA methylation of endogenous retroviruses is shaped by KRAB-ZFPs/KAP1 and ESET
Mao et al. Lentiviral vectors mediate long-term and high efficiency transgene expression in HEK 293T cells
Yi et al. Long noncoding RNA and its role in virus infection and pathogenesis
ATE225853T1 (de) Gewebe-spezifische promotoren
EP4541783A3 (de) Herstellung von terephthalsäureestern
Knight et al. Safer, silencing-resistant lentiviral vectors: optimization of the ubiquitous chromatin-opening element through elimination of aberrant splicing
RU2012130149A (ru) Векторная система на основе aslv
Guo et al. Chromatin-modifying elements for recombinant protein production in mammalian cell systems
RU2017101673A (ru) Способ получения ацетоина
JP2012531210A5 (de)
EP4196263C0 (de) Verfahren zur herstellung von geträgerten metall-katalysatoren mit einer als katalysatorträger eingesetzten kornförmigen aktivkohle
ATE338741T1 (de) Verfahren zur herstellung von phthalsäureanhydrid
DE60038555D1 (de) Verpackungszelle
AR019906A2 (es) Proceso para la produccion de acetato de vinilo mediante la reaccion de etileno, oxigeno y acido acetico como reactivos.
Kines et al. Expressing genes do not forget their LINEs: transposable elements and gene expression
Ge et al. Optimization of eGFP expression using a modified baculovirus expression system
WO2010099169A3 (en) A novel in vitro hiv-1 latency model for screening reactivation agents of hiv-1
Katzenberger et al. The Drosophila translational control element (TCE) is required for high-level transcription of many genes that are specifically expressed in testes
Šenigl et al. The core element of a CpG island protects avian sarcoma and leukosis virus-derived vectors from transcriptional silencing
ATE174056T1 (de) Verbesserung in zusammenhang mit dem nachweis von viren
Miyashita et al. Corrigendum: Long-term channelrhodopsin-2 (ChR2) expression can induce abnormal axonal morphology and targeting in cerebral cortex
Fujimoto et al. Antiviral effects against influenza A virus infection by a short hairpin RNA targeting the non-coding terminal region of the viral nucleoprotein gene
JP2011092196A5 (de)
Kostareva GENETICS OF THE LONG QT SYNDROME

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties